MapLight Therapeutics (MPLT) Operating Leases (2024 - 2025)
MapLight Therapeutics (MPLT) reported Operating Leases of $4.9 million for Q4 2025, down 15.34% on a YoY basis from $5.8 million in Q4 2024, and down 4.53% sequentially from $5.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Operating Leases (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Operating Leases data on file, last reported at $4.9 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Leases fell 15.34% year-over-year to $4.9 million; the trailing twelve-month figure through Dec 2025 stood at $4.9 million (down 15.34% YoY), and the FY2025 full-year result was $4.9 million, down 15.34% from the prior year.
- Operating Leases declined to $4.9 million in Q4 2025, from $5.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $5.8 million in Q4 2024 to a low of $4.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.91 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Dec 31, 2024 | 5.80 Mn |